| Drug General Information |
| Drug ID |
D0VB2W
|
| Former ID |
DNC002431
|
| Drug Name |
5-Nitroindazole
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C7H5N3O2
|
| Canonical SMILES |
C1=CC2=C(C=C1[N+](=O)[O-])C=NN2
|
| InChI |
1S/C7H5N3O2/c11-10(12)6-1-2-7-5(3-6)4-8-9-7/h1-4H,(H,8,9)
|
| InChIKey |
WSGURAYTCUVDQL-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
538954, 592910, 826403, 826432, 954272, 3134056, 5323473, 7736897, 7885421, 8165836, 14867454, 17153674, 24811413, 24852977, 24886549, 29197121, 29288888, 46505588, 49982566, 51075371, 57330910, 79078267, 81041508, 87573743, 87628205, 92715518, 99218232, 103420939, 104158505, 104353449, 104668500, 118017416, 118083072, 124952212, 125110004, 125352620, 126544028, 126579801, 126588544, 126592605, 126629228, 126654761, 126669003, 126737138, 127339851, 127339852, 127339853, 127341012, 127341013, 129626883
|
| Target and Pathway |
| Target(s) |
Nitric oxide synthase, inducible |
Target Info |
Inhibitor |
[1]
|
|---|
| Nitric-oxide synthase, endothelial |
Target Info |
Inhibitor |
[1]
|
|
BioCyc Pathway
|
Citrulline-nitric oxide cyclePWY-4983:Citrulline-nitric oxide cycle
|
|
KEGG Pathway
|
Arginine biosynthesis
|
|
Arginine and proline metabolism
|
|
Metabolic pathways
|
|
Calcium signaling pathway
|
|
HIF-1 signaling pathway
|
|
Peroxisome
|
|
Salmonella infection
|
|
Pertussis
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Amoebiasis
|
|
Tuberculosis
|
|
Pathways in cancer
|
|
Small cell lung cancerhsa00330:Arginine and proline metabolism
|
|
cGMP-PKG signaling pathway
|
|
Sphingolipid signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
VEGF signaling pathway
|
|
Platelet activation
|
|
Estrogen signaling pathway
|
|
Oxytocin signaling pathway
|
|
NetPath Pathway
|
IL1 Signaling Pathway
|
|
IL2 Signaling PathwayNetPath_8:Wnt Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
Endothelin signaling pathway
|
|
Interleukin signaling pathway
|
|
PI3 kinase pathway
|
|
VEGF signaling pathway
|
|
Pathway Interaction Database
|
IL12-mediated signaling events
|
|
Alpha9 beta1 integrin signaling events
|
|
ATF-2 transcription factor network
|
|
IL23-mediated signaling events
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
HIF-1-alpha transcription factor networker_nongenomic_pathway:Plasma membrane estrogen receptor signaling
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
Thromboxane A2 receptor signaling
|
|
SHP2 signaling
|
|
VEGFR1 specific signals
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
PAR1-mediated thrombin signaling events
|
|
Reactome
|
ROS production in response to bacteria
|
|
Nitric oxide stimulates guanylate cyclaseR-HSA-1222556:ROS production in response to bacteria
|
|
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
|
|
eNOS activation
|
|
Nitric oxide stimulates guanylate cyclase
|
|
VEGFR2 mediated vascular permeability
|
|
WikiPathways
|
Type II interferon signaling (IFNG)
|
|
Spinal Cord Injury
|
|
AGE/RAGE pathway
|
|
Effects of Nitric OxideWP554:ACE Inhibitor Pathway
|
|
EGF/EGFR Signaling Pathway
|
|
Myometrial Relaxation and Contraction Pathways
|
|
JAK/STAT
|
|
Corticotropin-releasing hormone
|
|
Endothelin Pathways
|
|
Leptin signaling pathway
|
|
Effects of Nitric Oxide
|
|
Metabolism of nitric oxide
|
|
Angiogenesis
|
| References |
| REF 1 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. |
|---|
